Single Photon Emission Computed Tomography of the Normal Human Brain
The objective of the study is to acquire a database of Single Photon Emission Computed Tomographic (SPECT) studies of the brains of normal human subjects in resting and concentrating states. The database will provide a basis for subsequent investigation of meaningful brain differences between clinical and normal subject groups
Normal Human Subjects
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Single Photon Emission Computed Tomography of the Normal Human Brain|
- Baseline SPECT image [ Time Frame: 24 hour assessment and data may be presented up to 10 years later as part of a normative database ] [ Designated as safety issue: No ]For the baseline resting study with adult subjects approximately 20 milliCuries of Tc-99m-hexamethylpropylene amine oxime (HMPAO, commercially marketed by Amersham Pharmaceuticals under the trade name Ceretec) will be injected after the initial equilibration period. Ceretec is an FDA-approved functional brain imaging radiopharmaceutical currently widely commercially available.
- Concentration SPECT image [ Time Frame: 24 hour assessment and data may be presented up to 10 years later as part of a normative database ] [ Designated as safety issue: No ]For the concentration study the subject will start the Conner's Continuous Performance Task, a 15-minute computer-administered test of attention, subsequent to the accommodation period. Three minutes into task performance HMPAO will be injected through the catheter with attention to minimal disruption of the subject's attention task. The subject will proceed to completion of the attention task.
|Study Start Date:||January 2003|
|Study Completion Date:||May 2010|
|Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
Healthy brain subjects
The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
See brief summary.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01203891
|United States, California|
|Amen Clinics, Inc.|
|Newport Beach, California, United States, 92660|
|Principal Investigator:||Daniel G Amen, MD||Amen Clinics, Inc.|